New Delhi: The Competition Commission of India (CCI) has cleared Mankind Pharma’s acquisition of Bharat Serums and Vaccines in a ₹13,630-crore deal.
In a statement on Wednesday, the regulator said: “The proposed transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines by Mankind Pharma.” Mankind had announced in July that it would acquire private equity firm Advent International’s 100% stake in Bharat Serums and Vaccines.
The move, experts say, would position Mankind as a leader in the Indian women’s health and fertility drug market.
Mankind is engaged in developing and marketing a diverse range of pharmaceutical finished dosage formulations, as well as several consumer healthcare products. Bharat Serums and Vaccines is engaged in manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients.
